IO Biotech, Inc. (IOBT) filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code on March 31, 2026, ending all operations in Delaware and initiating liquidation of the company’s assets. The filing follows a series of financial and regulatory setbacks that depleted the company’s cash reserves and eroded investor confidence.
The petition cites a $30.7 million cash balance that, according to company statements made in November 2025, would have supported operations only through the first quarter of 2026. Earlier in 2025 the company reduced its workforce by 50% in an effort to curb burn, but the remaining staff could not sustain the development of its lead oncology vaccine, Cylembio, or its pre‑clinical pipeline. The liquidation process will result in the delisting of IOBT shares from Nasdaq once the bankruptcy proceedings conclude.
The collapse was precipitated by the failure of Cylembio’s Phase 3 trial, which narrowly missed statistical significance on the primary progression‑free survival endpoint. In September 2025, the FDA issued a recommendation against submitting a Biologics License Application for Cylembio based on the trial data, a decision that removed the company’s primary revenue driver and forced a reevaluation of its business model. The setback intensified cash burn and accelerated the decision to file for bankruptcy.
Prior to the filing, IO Biotech had received multiple Nasdaq compliance notices for a bid price below $1.00 and a market value under $50 million, with deadlines to regain compliance in late 2025 and early 2026. The company’s stock had already fallen 59.9% after its Q3 2025 earnings release, and analysts at Morgan Stanley and Piper Sandler downgraded the stock in January 2026, citing liquidity concerns. These developments signaled a loss of confidence among investors and regulators, setting the stage for the bankruptcy filing.
The company’s European Investment Bank loan facility was triggered as an event of default upon the bankruptcy filing, further complicating the liquidation process. The EIB loan, which had been a key source of working capital, now represents a default that will be addressed in the liquidation proceedings. The combination of regulatory rejection, financial distress, and regulatory compliance failures culminated in the Chapter 7 filing, effectively ending IO Biotech’s operations as an independent entity.
"We had a productive meeting with FDA; while this is not the outcome we had hoped for, we respect FDA's feedback and remain confident in the therapeutic potential of Cylembio," said Mai‑Britt Zocca, PhD, president and chief executive officer of IO Biotech. "We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally, we plan to discuss the data from our IOB‑013 study with European regulators and determine a path to submission in the EU." (September 29, 2025)
"Although the IOB‑013 study narrowly missed statistical significance on the primary PFS endpoint, the results of the study support the mechanism of action of our therapeutic cancer vaccines and, we believe, have significantly de‑risked the program. We look forward to discussing the next Phase 3 study design for Cylembio with the FDA in December and remain committed to bringing Cylembio..." (November 14, 2025)
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.